Trial Profile
Evaluation of Paclitaxel in Patients With CLI (Critical Limb Ischemia) and Femoropopliteal Occlusive Disease Treated With DCB Angioplasty
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Chronic limb-threatening ischemia
- Focus Therapeutic Use
- 02 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 09 Jun 2022 Planned primary completion date changed from 1 May 2022 to 31 Dec 2022.
- 08 Jun 2022 Planned End Date changed from 1 Dec 2022 to 31 Dec 2022.